Shares of DexCom Inc. DXCM shed 9.30% to $61.80 Thursday, on what proved to be an all-around grim trading session for the ...

Sands Capital, an investment management company, released its “Sands Capital Select Growth Fund” Q4 2024 investor letter. A ...

DexCom Inc. closed 52.01% short of its 52-week high of $141.99, which the company achieved on April 9th.

The general mood among these heavyweight investors is divided, with 12% leaning bullish and 50% bearish. Among these notable ...

DexCom plans to launch its 15-day G7 sensor in the second half of 2025, pending FDA approval. A longer wear time may boost ...

DexCom DXCM recently signed a licensing and data partnership with a privately held healthcare-at-home digital diagnostics company — Nanowear. Per the terms of the agreement, Nanowear will use ...

Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Dexcom (DXCM – Research Report) yesterday and set a price target of $98.00. The ...

DexCom (DXCM) announced the appointment of Jon Coleman as chief commercial officer. In this role, Mr. Coleman will assume responsibility for ...

Intensifying competition from Abbott and Medtronic and the rise of GLP-1 drugs pose significant threats to DXCM's market position and growth projections. The valuation of DXCM at 43x non-GAAP ...